bioRxivImmunology
Cryo-EM structure of the NLRP3 decamer bound to the cytokine release inhibitory drug CRID3
I. V. Hochheiser, M. Pilsl, G. Hagelueken, J. Moecking, M. Marleaux, R. Brinkschulte, E. Latz, C. Engel, M. Geyer
Abstract
NLRP3 is an intracellular sensor protein whose activation by a broad spectrum of exogenous and endogenous stimuli leads to inflammasome formation and pyroptosis. The mechanisms leading to NLRP3 activation and the way how antagonistic small molecules function remain poorly understood. Here we report the cryo-electron microscopy structures of full-length NLRP3 in its native form and complexed with the inhibitor CRID3 (also named MCC950). Inactive, ADP-bound NLRP3 is a decamer composed of homodimers of intertwined LRR domains that assemble back-to-back as pentamers with the NACHT domain located at the apical axis of this spherical structure. Molecular contacts between the concave sites of two opposing LRRs are mediated by an acidic loop extending from an LRR transition segment. Binding of CRID3 significantly stabilizes the NACHT and LRR domains relative to each other, allowing structural resolution of 3.9-4.2 [A]. CRID3 binds into a cleft, connecting four subdomains of the NACHT with the transition LRR. Its central sulfonylurea group interacts with the Walker A motif of the NLRP3 nucleotide-binding domain and is sandwiched between two arginines from opposing sites, explaining the specificity of NLRP3 for this chemical entity. With the determination of the binding site of this lead therapeutic, specific targeting of NLRP3 for the treatment of autoinflammatory and autoimmune diseases and rational drug optimization are within reach.
- organism: human
- assay: cryo-EM
- research focus: protein structure prediction
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- MCC950/CRID3 potently targets the NACHT domain of wildtype NLRP3 but not disease-associated mutants for inflammasome inhibition
L. Vande Walle, I. B. Stowe, … M. Lamkanfi·bioRxiv·May 11, 2019
- Discovery of a Potent and Selective Inhibitor of Human NLRP3 with a Novel Binding Modality and Mechanism of Action
Kevin Wilhelmsen, Aditi Deshpande, … Rebecca C. Coll·The Journal of Experimental MedicinePeer-reviewed·Jul 24, 2025
- Inhibition of NLRP3 by a CNS-penetrating indazole scaffold
Jane Torp, Dominic Ferber, … Matthias Geyer·bioRxiv·Jul 1, 2025
- Structural Insights into the ATP-dependent Activation of NOD-like Receptor with Pyrin 3 (NLRP3) Protein by Molecular Dynamics Simulation
C. F. Sandall, J. A. MacDonald·bioRxiv·May 3, 2023
- The leucine-rich repeat (LRR) domain of NLRP3 is required for NLRP3 inflammasome activation in macrophages
- Covalent targeting as a common mechanism for inhibiting NLRP3 inflammasome assembly.
C. Stanton, J. Sun, … M. J. Bollong·bioRxiv·Jun 1, 2023